QURE
Closed
Uniqure Nv
13.99
+0.05 (+0.36%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 13.94
Day's Range: 13.645 - 14.2299
Send
sign up or login to leave a comment!
When Written:
18.76
Uniqure NV is a biotechnology company that focuses on developing gene therapies for patients with rare genetic diseases. The company was founded in 1999 and is headquartered in Amsterdam, Netherlands. Uniqure NV has a pipeline of gene therapies in development for a range of rare genetic diseases, including hemophilia, Huntington's disease, and metabolic disorders. The company's lead product, Glybera, was the first gene therapy to be approved in Europe in 2012 for the treatment of lipoprotein lipase deficiency. Uniqure NV also has partnerships with other biotechnology and pharmaceutical companies to develop and commercialize gene therapies. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol QURE.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








